- Home
- WINT vs SCNI Comparison
WINT vs SCNI Comparison
Compare WINT & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SCNI
- Stock Information
- Founded
- WINT 1992
- SCNI 2003
- Country
- WINT United States
- SCNI Israel
- Employees
- WINT N/A
- SCNI N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WINT Health Care
- SCNI Health Care
- Exchange
- WINT Nasdaq
- SCNI Nasdaq
- Market Cap
- WINT 4.8M
- SCNI 3.5M
- IPO Year
- WINT 1995
- SCNI N/A
- Fundamental
- Price
- WINT $2.80
- SCNI $3.60
- Analyst Decision
- WINT Hold
- SCNI
- Analyst Count
- WINT 1
- SCNI 0
- Target Price
- WINT $18.00
- SCNI N/A
- AVG Volume (30 Days)
- WINT 860.1K
- SCNI 14.6K
- Earning Date
- WINT 08-19-2024
- SCNI 10-29-2024
- Dividend Yield
- WINT N/A
- SCNI N/A
- EPS Growth
- WINT N/A
- SCNI N/A
- EPS
- WINT N/A
- SCNI N/A
- Revenue
- WINT N/A
- SCNI $284,000.00
- Revenue This Year
- WINT N/A
- SCNI N/A
- Revenue Next Year
- WINT N/A
- SCNI N/A
- P/E Ratio
- WINT N/A
- SCNI N/A
- Revenue Growth
- WINT N/A
- SCNI N/A
- 52 Week Low
- WINT $2.75
- SCNI $2.23
- 52 Week High
- WINT $27.00
- SCNI $13.70
- Technical
- Relative Strength Index (RSI)
- WINT 29.02
- SCNI 43.49
- Support Level
- WINT $10.20
- SCNI $3.52
- Resistance Level
- WINT $10.90
- SCNI $3.95
- Average True Range (ATR)
- WINT 1.37
- SCNI 0.28
- MACD
- WINT -1.16
- SCNI -0.05
- Stochastic Oscillator
- WINT 0.48
- SCNI 8.53
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.